Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
The development and progression of BC rely on a very complex signaling network that involves many different receptors aside from FGFR3 and VEGFR2.
|
25284004 |
2014 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Activating mutations of FGFR3 have been observed in up to 70% of non-muscle-invasive bladder tumors, while overexpression of a wild-type receptor, found in approximately 40% of tumors, has been correlated with more invasive disease.
|
22285006 |
2013 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Hsa_circ_0068871 regulates the miR-181a-5p/FGFR3 axis and activates STAT3 to promote BCa progression, and it may serve as a potential biomarker.
|
30999937 |
2019 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Silencing or inhibition of mutant FGFR3 in bladder cancer cell lines is associated with decreased malignant potential, confirming its important driver role in UC.
|
30952872 |
2019 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
FGFR3 analyses did not reveal any mutation in the urothelium from neither the control group nor the bladder cancer group.
|
19621447 |
2009 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Recent precision medicine has shown that mutations in BC are frequently observed in FGFR3, RAS and PIK3CA genes, all of which correlate with RAS signaling networks.
|
31066120 |
2019 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
An example of a TM domain pathogenic mutation is the Ala391-->Glu mutation in fibroblast growth factor receptor 3 (FGFR3), linked to Crouzon syndrome with acanthosis nigricans, as well as to bladder cancer.
|
16384584 |
2006 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
CTD_human |
Massively parallel sequencing of sperm DNA showed that levels of the FGFR3 mutation increase with paternal age and that the mutation spectrum at the Lys650 codon is similar to that observed in bladder cancer.
|
19855393 |
2009 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine.
|
16278395 |
2005 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
|
25657201 |
2015 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A sensitive and quantitative assay using peptide nucleic acid-mediated real-time PCR was developed for detecting FGFR3 mutations in the urine samples and evaluated as a molecular marker for detecting intravesical recurrence of NMIBC in patients undergoing transurethral resection of bladder tumor.
|
19843069 |
2010 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor receptor 3 (FGFR3) is an actionable target in bladder cancer.
|
27091807 |
2016 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We assessed the performance of associating a FGFR3 mutation assay and a DNA methylation analysis to improve bladder cancer detection and to predict disease recurrence of NMIBC patients.
|
27586786 |
2016 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We show that FGFR3 mutations are associated with a decreased risk of progression, and a better survival both in BC and in upper urinary tract cancer.
|
20123356 |
2010 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Somatic mutations of FGFR3 have been identified in bladder cancer, multiple myeloma, and other neoplasms.
|
16778799 |
2006 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
|
16885334 |
2006 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Based on this, we classified high-risk non-muscle-invasive bladder tumors according to FGFR3 mutations and chromosomal changes into papillary and CIS-type tumors with high correlation to CIS status (p = 0.001).
|
19637316 |
2009 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although activating mutations of fibroblast growth factor receptor 3 (FGFR3) are frequent in bladder tumors, little information is available on their specific effects in urothelial cells or the basis for the observed mutation spectrum.
|
19749790 |
2009 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Recent developments in the field of molecular mutational pathway analyses based on next generation sequencing technology together with classic data derived from the description of mutations in the FGFR3 (fibroblast growth factor receptor 3) gene, mutations on TP53 gene, and cDNA technology profiling data gives support to a differentiated taxonomy of bladder cancer.
|
25654736 |
2015 |
Bladder Neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our results indicate that both mutations and overexpression of FGFR3 are correlated together, and are more prevalent in early stage (pTa and pT1) and low grade (G1 and G2) bladder tumors.
|
20542753 |
2010 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
FGFR3 mutations were detected in 9/15 (60%) analyzed bladder tumors.
|
20957671 |
2011 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The two most important developments are the identification of a mutation in the fibroblast growth factor receptor 3 gene in more than 50% of urothelial carcinomas and the discovery of cDNA profiles characteristic of different subsets of bladder cancer.
|
19031931 |
2009 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
In contrast, there are very few studies on the impact of miRNA regulation on signaling by VHL (von Hippel-Lindau tumor suppressor) and vascular endothelial growth factor in renal cell carcinoma or by fibroblast growth factor receptor 3 and p53 in bladder cancer.
|
21632885 |
2011 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
The identification of mutations of FGF receptor 3 (FGFR3) in most noninvasive bladder tumors and the recent finding of overexpression of this receptor not only in superficial tumors but also in many invasive bladder cancers has generated optimism that therapies targeting this receptor tyrosine kinase may have major application in the treatment of urothelial cancers.
|
18241002 |
2008 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events.
|
20824703 |
2011 |